Short Interest in Starpharma Holdings Ltd. (OTCMKTS:SPHRY) Decreases By 99.0%

Starpharma Holdings Ltd. (OTCMKTS:SPHRY) was the target of a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 1 shares, a decline of 99.0% from the August 15th total of 101 shares. Based on an average daily volume of 769 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are short sold.

Starpharma Price Performance

OTCMKTS:SPHRY remained flat at $5.35 during mid-day trading on Thursday. The company had a trading volume of 1,000 shares, compared to its average volume of 644. The company has a 50-day moving average of $4.98 and a 200 day moving average of $4.49. Starpharma has a 12-month low of $0.74 and a 12-month high of $5.82.

Starpharma Company Profile

Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.

In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.